ANVS,Annovis Bio, Inc. | Healthcare

Healthcare

ANVS

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

Annovis Bio, Inc.ANVS

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration.

The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.

It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia.

The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Latest News >

Google agrees $36 million fine for anti-competitive deals with Australia telcos

Aug 17, 2025

SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...

Canagold Resources Provides "Positive" Feasibility Study Results for New Polaris Project in British Columbia

Jul 21, 2025

08:34 AM EDT, 07/21/2025 (MT Newswires) -- Canagold Resources ( CRCUF ) reported Monday positive results of a feasibility study for the New Polaris gold-antimony project in British Columbia. The project generated an after-tax net present value of $425 million, a 30.9% internal rate of return and a 2.4-year payback period, based on a 5% discount rate and a base...

Ryanair Keeps Max 10 Order After Boeing Assures Delivery in 2027

Jul 21, 2025

08:37 AM EDT, 07/21/2025 (MT Newswires) -- Ryanair ( RYAOF ) Chief Executive Michael O'Leary said Monday the company will not switch its order for Boeing ( BA ) Max 10 jets after receiving confirmation from Boeing ( BA ) that the aircraft will be delivered on time in the spring of 2027, according to a FactSet transcript of the...

Sensata Technologies Names Andrew Lynch as Chief Financial Officer

Jul 21, 2025

08:32 AM EDT, 07/21/2025 (MT Newswires) -- Sensata Technologies ( ST ) said Monday it has appointed Andrew Lynch as executive vice president and chief financial officer, effective immediately. Lynch joined Sensata ( ST ) in 2009. He most recently served as interim CFO. ...